AU2016228555B2 - Conjugates of an IL-7 moiety and a polymer - Google Patents

Conjugates of an IL-7 moiety and a polymer Download PDF

Info

Publication number
AU2016228555B2
AU2016228555B2 AU2016228555A AU2016228555A AU2016228555B2 AU 2016228555 B2 AU2016228555 B2 AU 2016228555B2 AU 2016228555 A AU2016228555 A AU 2016228555A AU 2016228555 A AU2016228555 A AU 2016228555A AU 2016228555 B2 AU2016228555 B2 AU 2016228555B2
Authority
AU
Australia
Prior art keywords
conjugate
moiety
och
polymer
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016228555A
Other languages
English (en)
Other versions
AU2016228555A1 (en
Inventor
Deborah H. Charych
Peter Benedict Kirk
Ping Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of AU2016228555A1 publication Critical patent/AU2016228555A1/en
Application granted granted Critical
Publication of AU2016228555B2 publication Critical patent/AU2016228555B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2016228555A 2015-03-11 2016-03-11 Conjugates of an IL-7 moiety and a polymer Active AU2016228555B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131634P 2015-03-11 2015-03-11
US62/131,634 2015-03-11
PCT/US2016/022146 WO2016145388A1 (en) 2015-03-11 2016-03-11 Conjugates of an il-7 moiety and an polymer

Publications (2)

Publication Number Publication Date
AU2016228555A1 AU2016228555A1 (en) 2017-08-31
AU2016228555B2 true AU2016228555B2 (en) 2021-12-23

Family

ID=56878892

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016228555A Active AU2016228555B2 (en) 2015-03-11 2016-03-11 Conjugates of an IL-7 moiety and a polymer

Country Status (11)

Country Link
US (1) US20190290733A1 (enExample)
EP (1) EP3285799A4 (enExample)
JP (3) JP2018510863A (enExample)
KR (2) KR20170125839A (enExample)
CN (1) CN107405384A (enExample)
AU (1) AU2016228555B2 (enExample)
CA (1) CA2978330C (enExample)
IL (1) IL254389B2 (enExample)
MA (1) MA41957A (enExample)
MX (1) MX391071B (enExample)
WO (1) WO2016145388A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
CA2664304C (en) 2006-09-28 2017-08-22 Schering Corporation Use of pegylated il-10 to treat cancer
HK1215681A1 (zh) 2013-04-18 2016-09-09 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
CA2928710A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CA2963995A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
HK1246201A1 (zh) 2015-05-28 2018-09-07 Armo Biosciences, Inc. 用於治疗癌症的聚乙二醇化白细胞介素-10
ES3039640T3 (en) 2015-08-25 2025-10-23 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders
US11702446B2 (en) 2018-12-12 2023-07-18 Levim Biotech Llp Acylation process for preparation of N-substituted peptide
WO2022020637A1 (en) * 2020-07-22 2022-01-27 Nektar Therapeutics Il-7 receptor agonist composition and related methods and uses
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012065086A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
WO2002085300A2 (en) * 2001-04-23 2002-10-31 The Regents Of The University Of California Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
RS53104A (sr) * 2001-11-20 2006-10-27 Pharmacia Corporation Hemijski modifikovani konjugati humanog hormona rasta
EP1391513A1 (en) * 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
MXPA05006945A (es) * 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor.
US7589179B2 (en) * 2004-12-09 2009-09-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
CN102037004A (zh) * 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
EP2780361B1 (en) * 2011-11-14 2018-01-17 Emory University Conjugates of gm-csf and il-7, compositions and methods related thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012065086A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer

Also Published As

Publication number Publication date
CN107405384A (zh) 2017-11-28
EP3285799A4 (en) 2018-08-08
MX391071B (es) 2025-03-21
KR20250052471A (ko) 2025-04-18
JP2022163194A (ja) 2022-10-25
US20190290733A1 (en) 2019-09-26
MX2017011562A (es) 2018-05-11
EP3285799A1 (en) 2018-02-28
IL254389B (en) 2022-11-01
IL254389B2 (en) 2023-03-01
MA41957A (fr) 2018-02-28
IL254389A0 (en) 2017-11-30
AU2016228555A1 (en) 2017-08-31
KR20170125839A (ko) 2017-11-15
WO2016145388A1 (en) 2016-09-15
JP2018510863A (ja) 2018-04-19
CA2978330A1 (en) 2016-09-15
JP2021091708A (ja) 2021-06-17
CA2978330C (en) 2024-01-09

Similar Documents

Publication Publication Date Title
AU2016228555B2 (en) Conjugates of an IL-7 moiety and a polymer
AU2022268401B2 (en) Conjugates of an IL-2 moiety and a polymer
EP3139947B1 (en) Conjugates of il-15 and branched polyethylene glycol
US20070092482A1 (en) Conjugates of a G-CSF moiety and a polymer
AU2009246851B2 (en) Conjugates of a cholinesterase moiety and a polymer
WO2013020079A2 (en) Conjugates of an il-11 moiety and a polymer
AU2005275108B2 (en) Conjugates of a GM-CSF moiety and a polymer
HK40053166A (en) Conjugates of an il-2 moiety and a polymer
HK1235666B (en) Conjugates of il-15 and branched polyethylene glycol
HK1235666A1 (en) Conjugates of il-15 and branched polyethylene glycol

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ CHARYCH, DEBORAH H.; ZHANG, PING AND KIRK, PETER BENEDICT

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ CONJUGATES OF AN IL-7 MOIETY AND A POLYMER

FGA Letters patent sealed or granted (standard patent)